Ansornitinib
Ansornitinib is an orally active dual kinase inhibitor that inhibits platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR2) . Ansornitinib can be used as an antifibrotic agent in lung, liver, kidney, and gastrointestinal fibrotic diseases[1].
Product Specifications
CAS Number
[1448874-96-1]
Product Name Alternative
ANG-3070
UNSPSC
12352005
Target
PDGFR; VEGFR
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/ansornitinib.html
Purity
98.04
Solubility
DMSO : 40 mg/mL (ultrasonic; warming; adjust pH to 2 with 1M HCl; heat to 80°C)
Smiles
CN(CC1)CCN1CC(N(C)C(C=C2)=CC=C2N/C(C3=CC=CC=C3)=C4C5=CC=C(C(OC)=O)N=C5NC/4=O)=O
Molecular Formula
C30H32N6O4
Molecular Weight
540.61
References & Citations
[1]Shakil ASLAM, et al. Reducing fibrosis and treating related diseases, disorders, and conditions. WO2022006278
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
Recombinant Escherichia coli O157:H7 4-hydroxybenzoate octaprenyltransferase (ubiA)
Recombinant Escherichia coli O157:H7 4-hydroxybenzoate octaprenyltransferase (ubiA)
Recombinant Escherichia coli O157:H7 4-hydroxybenzoate octaprenyltransferase (ubiA)
